A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices.
Jonathan E KnikmanHilde RosingHenk-Jan GuchelaarA CatsJos H BeijnenPublished in: Biomedical chromatography : BMC (2020)
The bioanalysis of the oral anticancer drug capecitabine and its metabolites has been investigated extensively over the past years. This paper reviews methods for the bioanalysis of capecitabine and its metabolites. The focus of this review will be on sample pre-treatment, chromatography and detection. Furthermore, the choice of standards and analytical problems encountered during analysis of capecitabine and its metabolites in biological matrices will be discussed. The major challenges in the bioanalysis of capecitabine and its metabolites are the simultaneous extraction and analysis due to the differences in polarity of the analytes. Furthermore we evaluate currently described methods for the quantification of capecitabine and its metabolites. Future wishes and perspectives are stated that could serve as an inspiration for further development of assays for the quantification of capecitabine and its metabolites.
Keyphrases
- ms ms
- phase ii study
- locally advanced
- metastatic breast cancer
- metastatic colorectal cancer
- phase iii
- squamous cell carcinoma
- mental health
- clinical trial
- rectal cancer
- open label
- mass spectrometry
- systematic review
- high resolution
- multidrug resistant
- liquid chromatography
- high throughput
- high speed
- combination therapy
- drug induced
- single molecule
- electronic health record
- decision making
- meta analyses